Mexico - Delayed Quote • MXN MoonLake Immunotherapeutics (MLTXN.MX) Follow Add holdings 1,074.20 +118.12 +(12.35%) At close: December 10 at 1:33:24 PM CST Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure Undo Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for MLTXN.MX 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: MLTXN.MX View more All News Press Releases SEC Filings Constellation and Meta, Merck, Snowflake: Trending Tickers MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation? MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis